Table 3.

Detailed Survey Responses About Diagnostic Evaluation, Treatment, and Follow-Up of SCH During Pregnancy

Survey Responses	n (%)
TSH cutoff
Fixed cutoff of TSH >2.5 mIU/L	77 (52.4)
Fixed cutoff of TSH >4.0 mIU/L	37 (25.2)
Population-based cutoff	8 (5.4)
According to TPO-Ab status	7 (4.8)
According to clinical features	7 (4.8)
Nonpregnant adult cutoff	6 (4.1)
Other or unknown	5 (3.3)
FT4 measurement
When TSH is higher than pregnancy-specific cutoff	72 (49.0)
Always	53 (36.1)
Never	9 (6.1)
When TSH >10.0 mIU/L	7 (4.8)
Other or unknown	6 (4.0)
TPO-Ab measurement
When TSH is higher than pregnancy-specific cutoff	64 (43.5)
Always	57 (38.8)
Never	12 (8.2)
Other or unknown	12 (8.2)
When TSH >10.0 mIU/L	2 (1.4)
Medication choicea
LT4	143 (97.3)
LT4 + liothyronine (T3)	4 (2.7)
Thyroid extracts	3 (2.0)
Thyroid hormone initial dose
Fixed small dose (25–50 µg/d)	104 (70.8)
Dose based on patient’s TSH level	17 (11.6)
Fixed full dose (75–100 µg/d)	12 (8.2)
Dose based on patient’s weight	11 (7.4)
Other dose	3 (2.0)
TSH follow-up until midgestation
On everyone, every 4–6 wk	95 (64.6)
Only if TSH is not appropriate at first check after LT4 initiation	26 (17.7)
On everyone, every 6–8 wk	8 (5.4)
On everyone, every trimester	7 (4.8)
On everyone, every 2–4 wk	6 (4.0)
Never	3 (2.0)
Other or unknown	2 (1.4)
TSH treatment goal
TSH <2.5 mIU/L	108 (73.5)
TSH in the lower half of the trimester-specific reference range	18 (12.2)
TSH <4.0 mIU/L	13 (8.8)
Other or unknown	7 (4.8)
TSH between normal limits for a nonpregnant adult	1 (0.7)
Indication to stop LT4 treatment postpartum
TSH level postpartum within normal limits for a nonpregnant adult	51 (34.7)
Women who used LT4 <50 μg daily	26 (17.7)
All the postpartum women	25 (17.0)
Women with TPO-Ab negative	19 (12.9)
No indication to stop LT4 treatment	10 (6.8)
Other indications	9 (6.1)
Women with normal thyroid function prior to pregnancy	4 (2.7)
Decision according to patient preferences	3 (2.0)

^aMultiselect and multiple choice question.